10:35 AM EDT, 04/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trimmed our target price to USD86 from USD89 and keep our EPADS estimated USD4.58 for 2025 and USD5.09 for 2026. Our target price implies 18.8x our 2025 EPADS estimate, in line with its five-year historical forward P/E. We like AZN for its strong pipeline and the numerous key data readouts anticipated in 2025. We expect existing key products, a strong pipeline, and contributions from acquisitions to drive growth toward its USD80 billion revenue target by 2030. In Q1 2025, AZN reported total revenue of USD13.6 billion, slightly missing consensus of USD13.7 billion, while core EPS of USD2.49 beat consensus of USD2.24, partly helped by tax adjustments. With regards to the potential tariffs issues, AZN said it is committed to investing in the U.S. and had previously committed to investing USD3.5 billion in the country.